Entering text into the input field will update the search result below

Cerecor shares rise 5% as mAb shows promise in small COVID-19 trial

Apr. 07, 2021 12:25 PM ETKYKOF, AVTXBy: Jonathan Block, SA News Editor1 Comment
  • CERC-002, a monoclonal antibody (mAB) from Cerecor (NASDAQ:CERC), reduced respiratory failure and death in a small trial of hospitalized COVID-19 patients.
  • Results, published as a preprint in medRxiv and not yet peer reviewed, found that 83.9% of patients with acute respiratory distress

Recommended For You